Revolution Medicines, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RVMD | ERAS | NUVL | RLAY | 9995.HK | GMAB | |
|---|---|---|---|---|---|---|
| Market cap | 42.80B | 5.21B | — | 3.95B | 40.23B | 33.89B |
| P/E (TTM) | — | — | — | — | 6.1 | 43.4 |
| Forward P/E | -34.6 | -23.9 | — | -11.0 | 46.7 | 34.9 |
| Price/book | 24.1 | 12.9 | — | 5.5 | 3.8 | 5.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +225.35% | +565.63% | — | +176.11% | −19.94% | +91.12% |
| Today | +2.82% | +1.84% | 0.00% | +3.38% | +1.49% | −0.72% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RVMD news ›Revolution Medicines rises on Q3 beats; maintains 2026 guidance
Revolution Medicines beats Q3 estimates as Rasonque sales hit $197.6M and 2026 expense guidance holds. Read more here. - Revolution Medicines is ~~6% higher in after-hours trading Wednesday after posting Q3 financial results that beat on…
Revolution Medicines (RVMDW) Projected to Post Quarterly Earnings on Wednesday
Posted by Michael Walen on Nov 2nd, 2026 Revolution Medicines (NASDAQ:RVMDW – Get Free Report) is expected to release its results after the market closes on Wednesday, November 4th. Analysts expect Revolution Medicines to post earnings of…
Amylyx Pharmaceuticals (NASDAQ:AMLX) & Revolution Medicines (NASDAQ:RVMD) Head-To-Head Contrast
Posted by Mitch Edgeman on Oct 30th, 2026 Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the…
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
The biotech has experienced a pullback in recent weeks. Revolution Medicines (RVMD +1.34%) has been one of the hottest biotech stocks this year, thanks to meaningful clinical and regulatory progress with its most important product,…
Could Revolution Medicines Be a Millionaire-Maker Stock?
A return of over 9x in just three years. That's the sizzling trajectory for Revolution Medicines (RVMD +1.34%). It's one of the hottest biotech stocks of 2026, with shares soaring more than 130%. Revolution Medicines' performance is the…
TD Cowen Remains a Buy on Revolution Medicines (RVMD)
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines today and set a price target of $250.00. Van Buren covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Gilead Sciences, and…
More from 1 other outlet
Revolution Medicines presents subgroup analyses from RASolute 302 trial
Revolution Medicines (RVMD) announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking a... Revolution Medicines presents subgroup analyses from RASolute 302 trial Revolution…
Revolution Medicines begins treating patients in RASolve 308 trial
Revolution Medicines (RVMD) announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib... Revolution Medicines begins treating patients in RASolve 308 trial Revolution Medicines…
Lightning Round: Penguin Solutions and Revolution Medicines
Penguin Solutions and Revolution Medicines. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ... Lightning Round: Penguin Solutions and…
Tango Therapeutics Stock Tumbles 16% Despite 82% Response Rate in Pancreatic Cancer Combo Trial at ESMO
NEW YORK — Tango Therapeutics shares fell more than 16% in early trading Friday. The biotech company presented updated results for its pancreatic cancer drug combination at a major medical meeting, but investors sold the stock after a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- fool.com3
- gurufocus.com3
- themarketsdaily.com3
- defenseworld.net2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 31 articles, not a forecast.